Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer

Tumori

Volumn 93, Issue 2, 2007, Pages 129-132

  Osato, Tomo ^a   Ito, Yoshinori ^a   Takahashi, Shunji ^a   Tokudome, Nahomi ^a   Iwase, Takuji ^a   Hatake, Kiyohiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Capecitabine monotherapy; Heavily pretreated; Low dose intensity; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERCEPTION DEAFNESS; REVIEW; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 34249892537     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300203     Document Type: Review

References (12)

1. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 34: 1274-1281, 1998.
2. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol, 16: 2977-2985, 1998.
3. Saeki T, Takashima S, Terashima M, Satoh A, Toi M, Osaki A, Toge T, Ohno S, Nomura N, Fukuyama Y, Koizumi W, Taguchi T: A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors. Int J Clin Oncol, 10: 51-57, 2005.
4. Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. Clin Oncol, 23: 2155-2161, 2005.
5. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S: Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol, 12: 1247-1254, 2001.
6. Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B: Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer, 86: 1367-1372, 2002.
7. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 17: 485-493, 1999.
8. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 92: 1759-1768, 2001.
9. Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Luck HJ: Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol, 14: 1227-1233, 2003.
10. Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillemin E, Morere JF, Montestruc F, Mouri Z, Namer M: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer, 40: 536-542, 2004.
11. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I: Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol, 43: 186-189, 2004.
12. Saeki T, Kimura T, Toi M, Taguchi T: A pilot phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer, 13: 49-57, 2006.